Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Susanne J. Goldie, M.D.

Co-Author

This page shows the publications co-authored by Susanne Goldie and Elena Losina.
Connection Strength

0.973
  1. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr. 2006 Dec 01; 43 Suppl 1:S113-8.
    View in: PubMed
    Score: 0.086
  2. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med. 2006 Sep 14; 355(11):1141-53.
    View in: PubMed
    Score: 0.085
  3. Diagnostic tests in HIV management: a review of clinical and laboratory strategies to monitor HIV-infected individuals in developing countries. Bull World Health Organ. 2006 Jul; 84(7):581-8.
    View in: PubMed
    Score: 0.084
  4. Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire. S Afr Med J. 2006 Jun; 96(6):526-9.
    View in: PubMed
    Score: 0.083
  5. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003 Dec 01; 115(8):632-41.
    View in: PubMed
    Score: 0.070
  6. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002 Nov 25; 162(21):2478-86.
    View in: PubMed
    Score: 0.065
  7. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med. 2002 Apr 22; 162(8):921-8.
    View in: PubMed
    Score: 0.062
  8. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001 Mar 15; 344(11):824-31.
    View in: PubMed
    Score: 0.058
  9. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med. 2011 Feb; 12(2):97-108.
    View in: PubMed
    Score: 0.029
  10. Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One. 2010 Sep 09; 5(9).
    View in: PubMed
    Score: 0.028
  11. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr. 2010 Jul; 54(3):258-68.
    View in: PubMed
    Score: 0.028
  12. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis. 2008 May 01; 197(9):1324-32.
    View in: PubMed
    Score: 0.024
  13. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med. 2007 Oct; 8(7):439-50.
    View in: PubMed
    Score: 0.023
  14. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS. 2007 May 11; 21(8):973-82.
    View in: PubMed
    Score: 0.022
  15. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005 Nov 01; 41(9):1316-23.
    View in: PubMed
    Score: 0.020
  16. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS. 2005 Aug 12; 19(12):1299-308.
    View in: PubMed
    Score: 0.020
  17. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005 May 01; 39(1):69-77.
    View in: PubMed
    Score: 0.019
  18. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. Antivir Ther. 2005; 10(1):41-52.
    View in: PubMed
    Score: 0.019
  19. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. Clin Infect Dis. 2003 Jan 01; 36(1):86-96.
    View in: PubMed
    Score: 0.016
  20. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther. 2002 Dec; 7(4):257-66.
    View in: PubMed
    Score: 0.016
  21. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr. 2002 Sep 01; 31(1):27-37.
    View in: PubMed
    Score: 0.016
  22. The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality. J Acquir Immune Defic Syndr. 2002 Aug 01; 30(4):421-8.
    View in: PubMed
    Score: 0.016
  23. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making. 2002 Jan-Feb; 22(1):27-38.
    View in: PubMed
    Score: 0.015
  24. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health. 2001 Sep; 91(9):1456-63.
    View in: PubMed
    Score: 0.015
  25. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol. 2001 Aug; 30(4):864-71.
    View in: PubMed
    Score: 0.015
  26. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001 Mar 20; 134(6):440-50.
    View in: PubMed
    Score: 0.014
  27. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin Infect Dis. 2001 Mar 01; 32(5):783-93.
    View in: PubMed
    Score: 0.014
  28. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making. 1998 Apr-Jun; 18(2 Suppl):S93-105.
    View in: PubMed
    Score: 0.012
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.